Product Overview
Dirucotide (formally named MBP8298) is a synthetic peptide that consists of 17 amino acids linked in a sequence identical to that of a portion of human myelin basic protein (MBP). Dirucotide has been developed for the treatment of multiple sclerosis (MS) and is based on over 26 years of research.
The Company has completed its substantive review of the data from the late-stage trials for dirucotide. BioMS has decided that it will explore a compassionate access and research program with limited financial commitment, but that it will not pursue further late stage clinical trials with dirucotide in MS. For further information please click here.